Sammyall, thanks for the reminder, but you haven't made me sleep any easier. So PAR's patents are for BME, not OA. Does that mean anyone can treat OA with PPS without infringing the patent? Can Bene sell PPS to a competitor if it's for 'pain relief'? Can a Big Pharma company run a combined safety-efficacy trial using the Indian PPS for OA and have a drug on the market 2 years after Zilosul without patent infringement?
This is the problem with relying on compounds that are off-patent.
PAR Price at posting:
$1.42 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)